Needham Investment Management LLC grew its stake in shares of Transcat, Inc. (NASDAQ:TRNS - Free Report) by 28.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 50,700 shares of the scientific and technical instruments company's stock after buying an additional 11,200 shares during the period. Needham Investment Management LLC owned 0.54% of Transcat worth $5,361,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Jones Financial Companies Lllp grew its stake in shares of Transcat by 686.7% during the 4th quarter. Jones Financial Companies Lllp now owns 354 shares of the scientific and technical instruments company's stock valued at $37,000 after buying an additional 309 shares during the period. Aquatic Capital Management LLC boosted its position in Transcat by 1,052.0% during the 4th quarter. Aquatic Capital Management LLC now owns 1,152 shares of the scientific and technical instruments company's stock worth $122,000 after purchasing an additional 1,052 shares during the period. Morgan Dempsey Capital Management LLC purchased a new stake in Transcat during the 4th quarter worth $143,000. SG Americas Securities LLC purchased a new stake in Transcat during the 4th quarter worth $182,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Transcat during the 4th quarter worth $190,000. 98.34% of the stock is owned by hedge funds and other institutional investors.
Transcat Price Performance
Shares of Transcat stock traded up $0.36 on Friday, hitting $81.25. The company had a trading volume of 188,080 shares, compared to its average volume of 78,766. The business has a 50-day simple moving average of $77.67 and a 200-day simple moving average of $89.95. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.42 and a quick ratio of 1.98. The company has a market cap of $756.36 million, a PE ratio of 43.92 and a beta of 0.69. Transcat, Inc. has a 52 week low of $67.56 and a 52 week high of $147.12.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on the stock. HC Wainwright decreased their price target on shares of Transcat from $126.00 to $106.00 and set a "buy" rating for the company in a research report on Wednesday, January 29th. StockNews.com cut shares of Transcat from a "hold" rating to a "sell" rating in a research report on Wednesday, February 5th. Oppenheimer cut shares of Transcat from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 29th. Finally, Northland Securities reiterated a "market perform" rating and issued a $85.00 price objective (down previously from $110.00) on shares of Transcat in a report on Wednesday, January 29th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $111.50.
Get Our Latest Report on TRNS
Transcat Profile
(
Free Report)
Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.
Featured Articles
Before you consider Transcat, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Transcat wasn't on the list.
While Transcat currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
